Andrew M Boal
Overview
Explore the profile of Andrew M Boal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boal A, McGrady N, Holden J, Risner M, Calkins D
Front Neurosci
. 2023 Apr;
17:1142668.
PMID: 37051140
Introduction: Identification of early adaptive and maladaptive neuronal stress responses is an important step in developing targeted neuroprotective therapies for degenerative disease. In glaucoma, retinal ganglion cells (RGCs) and their...
2.
McGrady N, Boal A, Risner M, Taiel M, Sahel J, Calkins D
Mol Ther
. 2023 Apr;
31(7):2005-2013.
PMID: 37016579
Lenadogene nolparvovec (GS010) was developed to treat a point mutation in mitochondrial ND4 that causes Leber hereditary optic neuropathy. GS010 delivers human cDNA encoding wild-type ND4 packaged into an rAAV2/2...
3.
Boal A, McGrady N, Chamling X, Kagitapalli B, Zack D, Calkins D, et al.
Transl Vis Sci Technol
. 2023 Apr;
12(4):1.
PMID: 37010860
Purpose: Axons depend on long-range transport of proteins and organelles which increases susceptibility to metabolic stress in disease. The axon initial segment (AIS) is particularly vulnerable due to the high...
4.
Naguib S, DeJulius C, Backstrom J, Haider A, Ang J, Boal A, et al.
Antioxidants (Basel)
. 2023 Mar;
12(3).
PMID: 36978804
Erythropoietin (EPO) is neuroprotective in multiple models of neurodegenerative diseases, including glaucoma. EPO-R76E retains the neuroprotective effects of EPO but diminishes the effects on hematocrit. Treatment with EPO-R76E in a...
5.
McGrady N, Holden J, Ribeiro M, Boal A, Risner M, Calkins D
Brain Commun
. 2022 Oct;
4(5):fcac251.
PMID: 36267329
Optic neuropathies are characterized by degeneration of retinal ganglion cell axonal projections to the brain, including acute conditions like optic nerve trauma and progressive conditions such as glaucoma. Despite different...
6.
Boal A, McGrady N, Risner M, Calkins D
Front Cell Neurosci
. 2022 Aug;
16:966425.
PMID: 35990894
Neuronal type-specific physiologic heterogeneity can be driven by both extrinsic and intrinsic mechanisms. In retinal ganglion cells (RGCs), which carry visual information from the retina to central targets, evidence suggests...
7.
Holden J, Al Awamlh S, Croteau L, Boal A, Rex T, Risner M, et al.
Int J Mol Sci
. 2022 Mar;
23(6).
PMID: 35328488
The nitric oxide-guanylyl cyclase-1-cyclic guanylate monophosphate (NO-GC-1-cGMP) pathway is integral to the control of vascular tone and morphology. Mice lacking the alpha catalytic domain of guanylate cyclase () develop retinal...
8.
Boal A, Risner M, Cooper M, Wareham L, Calkins D
Cells
. 2021 Jul;
10(6).
PMID: 34199470
Astrocytes are intimately involved in the response to neurodegenerative stress and have become an attractive target for the development of neuroprotective therapies. However, studies often focus on astrocytes as single-cell...
9.
Risner M, McGrady N, Boal A, Pasini S, Calkins D
Front Cell Neurosci
. 2021 Jan;
14:603419.
PMID: 33505248
Early progression in neurodegenerative disease involves challenges to homeostatic processes, including those controlling axonal excitability and dendritic organization. In glaucoma, the leading cause of irreversible blindness, stress from intraocular pressure...
10.
Moore B, Li K, Kaas J, Liao C, Boal A, Mavity-Hudson J, et al.
J Comp Neurol
. 2018 Aug;
527(3):577-588.
PMID: 30078198
Comprised of at least five distinct nuclei, the pulvinar complex of primates includes two large visually driven nuclei; one in the dorsal (lateral) pulvinar and one in the ventral (inferior)...